These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37574431)

  • 21. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
    Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis.
    Zahn A; Hinz U; Karner M; Ehehalt R; Stremmel W
    Inflamm Bowel Dis; 2006 Nov; 12(11):1058-67. PubMed ID: 17075347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
    Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    Reinisch W; Gibson PR; Sandborn WJ; Feagan BG; Strauss R; Johanns J; Padgett L; Adedokun OJ; Colombel JF; Collins J; Rutgeerts P; Tarabar D; Marano C
    J Crohns Colitis; 2018 Aug; 12(9):1053-1066. PubMed ID: 29917070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
    Taxonera C; Iborra M; Bosca-Watts MM; Rubio S; Nantes Ó; Higuera R; Bertoletti F; Martínez-Montiel P; Sierra-Ausin M; Manceñido N; Lázaro Pérez-Calle J; Algaba A; Olivares D; Alba C
    Curr Med Res Opin; 2019 Jul; 35(7):1297-1304. PubMed ID: 30722703
    [No Abstract]   [Full Text] [Related]  

  • 32. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
    J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
    Ghosh S; Sanchez Gonzalez Y; Zhou W; Clark R; Xie W; Louis E; Loftus EV; Panes J; Danese S
    J Crohns Colitis; 2021 Dec; 15(12):2022-2030. PubMed ID: 34107013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment.
    Casellas F; Robles V; Borruel N; Torrejón A; Castells I; Navarro E; Guarner F
    J Crohns Colitis; 2012 Oct; 6(9):881-6. PubMed ID: 22398074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
    Hodgkins P; Yen L; Yarlas A; Karlstadt R; Solomon D; Kane S
    Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
    Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
    Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
    Eriksson C; Visuri I; Vigren L; Nilsson L; Kärnell A; Hjortswang H; Bergemalm D; ; Almer S; Hertervig E; Karlén P; Strid H; Halfvarson J
    Scand J Gastroenterol; 2021 Nov; 56(11):1304-1311. PubMed ID: 34415803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year.
    Jo IH; Lee KM; Kim DB; Kim JW; Lee J; Jeen YT; Kim TO; Kim JS; Park JJ; Hong SN; Park DI; Kim HS; Lee YJ; Kim Y
    Gut Liver; 2022 May; 16(3):384-395. PubMed ID: 34373363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab for moderate to severe ulcerative colitis.
    Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.